Gemcitabine plus Paclitaxel as First-Line Chemotherapy for Patients with Advanced Breast CancerDelfino C.a · Caccia G.a · Gonzáles L.R.b · Mickiewicz E.c · Rodger J.c · Balbiani L.d · Morales D.F.b · Comba A.Z.d · Brosio C.c
aHospital Privado de Comunidad, Mar del Plata, Argentina; bHospital Nacional Edgardo Rebagliati Martins, Lima, Perú; cInstituto de Oncología Ángel H. Roffo, and dSanatorio Municipal Julio Méndez, BuenosAires, Argentina
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objectives: To assess the efficacy and tolerability of gemcitabine and paclitaxel as first-line treatment in advanced breast cancer. Methods: Patients with histologically confirmed metastatic or metastatic plus locally advanced breast cancer received gemcitabine 1,200 mg/m2 on days 1 and 8 and paclitaxel 175 mg/m2 on day 1 every 21 days for 8 cycles. Results: From December 1999 to August 2001, 45 patients, with a median age of 53.5 years (range, 22–77), received a total of 260 cycles. All were assessable for response and toxicity. Twenty-seven patients had prior adjuvant therapy. Hormonal receptor status was positive in 31.1% and negative in 40.0% of patients. Main metastatic sites included soft tissue (62.2%) and lung (53.3%). The objective response rate was 66.7%; complete response, 22.2%; partial response, 44.4%; stable disease, 15.6%; progressive disease, 17.8%. Median duration of response was 18 months and median time to tumor progression was 11 months. Grade 3/4 leukopenia, neutropenia, and thrombocytopenia developed in 13.3% of patients, and 15.5% developed grade 3/4 mucositis. No treatment-related deaths occurred. Median overall survival was 19 months. Conclusion: Gemcitabine plus paclitaxel is an active combination with a favorable toxicity profile as first-line treatment for patients with advanced breast cancer.
© 2004 S. Karger AG, Basel
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK (eds): SEER Cancer Statistics Review, 1975–2000, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975–2000, 2003.
Mouridsen H: Systemic therapy of advanced breast cancer. Drugs 1992;44:17–28.
Nabholtz JM, Falkson G, Campos D, et al: A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC (abstract 485). Proc Am Soc Clin Oncol 1999;18:127a.
- Belotti D, Vergani V, Drudis T, et al: The microtubule drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843–1849.
- Verschueren H, Dewit J, DeBraekeller J, et al: Motility and invasive potency of murine T-lymphoma cells: Effect of microtubule inhibitors. Cell Biol Int 1994;128:11–19.
- Stracke ML, Soroush M, Liotta LA, et al: Cytoskeletal agents inhibit motility and adherence of human tumor cells. Kidney Int 1993;43:151–157.
- Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000;18:724–733.
- Bishop JF, Dewar J, Toner GC, et al: Initial paclitaxel improves outcome compared with CMVP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999;17:2355–2364.
- Smith RE, Brown AM, Mamounas EP, et al: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-26. J Clin Oncol 1999;17:3403–3411.
- Heinemann V, Hertel LW, Gindley GB, et al: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1β-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024–4031.
- Guchelar HJ, Richel DJ, Van Knapen A: Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 1996;222:15–31.
Plunkett W, Huang P, Xu YZ, et al: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3–10.
- Huang P, Chubb S, Hertel L, et al: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110–6117.
- Boven E, Schipper H, Erkelens CAM, et al: The influence of the schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancers. Br J Cancer 1993;68:52–56.
- O’Shaughnessy JA, Cowan KH: Current status of paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat 1995;33:27–37.
Capri G, Tarenzi E, Fulfaro F, et al: The role of taxanes in the treatment of breast cancer. Semin Oncol 1996;23(1 suppl 2):68–75.
Carmichael J: The role of gemcitabine in the treatment of other tumors. Br J Cancer 1998;78(suppl 3):21–25.
Qu G, Perez EA: Gemcitabine and targeted therapy in metastatic breast cancer. Semin Oncol 2002;29(3 suppl 11):44–52.
- Blackstein M, Vogel CL, Ambinder R, et al: Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 2002;62:2–8.
- Possinger K, Kaufmann M, Coleman R, et al: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999;10:155–162.
Colomer R, Llombart A, Lluch A, et al: Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: Preliminary results of a phase II trial. Semin Oncol 2000;27(1 suppl 2):20–24.
- Murad AM, Guimaraes RC, Aragao BC, et al: Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am J Clin Oncol 2001;24:264–268.
Conte P, Salvadori B, Donati S, et al: Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. Semin Oncol 2001;28(2 suppl 7):15–17.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.